NCT06302023

Docosahexaenoic Acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm Labor

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Khon Kaen University · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical trial is to learn about the effects of Docosahexaenoic acid (DHA) in reducing the incidence of premature birth in threatened preterm labor The main questions it aims to answer are: * Can DHA supplementation reduce the incidence of premature birth in threatened preterm labor? * How does DHA supplementation affect pregnancy outcomes? Participants were organized into two groups * Group 1 (Intervention) Participants will be asked to take a DHA 1000mg per day * Group 2 (control) Participant will not need to take a DHA

Detailed description

Threatened preterm labor is defined as regular uterine contractions occurring before 37 completed weeks of gestation, without any cervical dilation.

Conditions

• Pregnant Women Diagnosed With Threatened Preterm Labor

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Docosahexaenoic acid (DHA) 1000 mg	Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age

Timeline

• Start date: 2024-04-01
• Primary completion: 2024-10-07
• Completion: 2024-10-07
• First posted: 2024-03-08
• Last updated: 2024-12-12

Locations

1 site across 1 country: Thailand